Introducing FDG PET/CT-guided chemoradiotherapy for stage III NSCLC in low- and middle-income countries: preliminary results from the IAEA PERTAIN trial-Reference-Cited by-同舟云学术

Introducing FDG PET/CT-guided chemoradiotherapy for stage III NSCLC in low- and middle-income countries: preliminary results from the IAEA PERTAIN trial

Published:2019-07-31 Issue:11 Volume:46 Page:2235-2243
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Konert T.^ORCID,Vogel W. V.,Paez D.,Polo A.,Fidarova E.,Carvalho H.,Duarte P. S.,Zuliani A. C.,Santos A. O.,Altuhhova D.,Karusoo L.,Kapoor R.,Sood A.,Khader J.,Al-Ibraheem A.,Numair Y.,Abubaker S.,Soydal C.,Kütük T.,Le T. A.,Canh N. X.,Bieu B. Q.,Ha L. N.,Belderbos J. S. A.,MacManus M. P.,Thorwarth D.,Hanna G. G.

Publisher

Springer Science and Business Media LLC

Subject

Radiology Nuclear Medicine and imaging,General Medicine,Radiology Nuclear Medicine and imaging,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00259-019-04421-5.pdf

Reference31 articles.

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

2. Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023–75.

3. Ung YC, Bezjak A, Coakley N, Evans WK; the Lung Cancer Disease Site Group of Cancer Care Ontario. Positron emission tomography with 18fluorodeoxyglucose in radiation treatment planning for non-small cell lung cancer: a systematic review. J Thorac Oncol. 2011;6:86–97.

4. Gregory DL, Hicks RJ, Hogg A, Binns DS, Shum PL, Milner A, et al. Effect of PET/CT on management of patients with non-small cell lung cancer: results of a prospective study with 5-year survival data. J Nucl Med. 2012;53:1007–15.

5. Badar F, Mahmood S, Yusuf MA, Sultan F. Epidemiology of cancers in Lahore, Pakistan, 2010–2012: a cross-sectional study. BMJ Open. 2016;6:e011828.

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of molecular subtypes and a prognostic signature based on m6A/m5C/m1A-related genes in lung adenocarcinoma;Scientific Reports;2024-03-30

2. A Glimpse Into the Future for Unresectable Stage III Non-Small Cell Lung Cancer;International Journal of Radiation Oncology*Biology*Physics;2023-12

3. Feasibility of omitting the clinical target volume under PET-CT guidance in unresectable stage III non-small-cell lung cancer: A phase II clinical trial;Radiotherapy and Oncology;2023-04

4. Clinical use of positron emission tomography for radiotherapy planning – Medical physics considerations;Zeitschrift für Medizinische Physik;2023-02

5. Working at the Intersection of Radiology and Global Health Equity;Applied Radiology;2023-01-01